The effects of quercetin on oxidative stress and fibrosis markers in chronic kidney disease rat model

Kamalia Layal, Ika S. Perdhana, Melva Louisa, Ari Estuningtyas, Vivian Soetikno



DOI: http://dx.doi.org/10.13181/mji.v26i3.1462

Abstract


Background: Oxidative stress may play a role in the pathogenesis of (CKD), Nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcription factor involved in cell defense mechanism against oxidative stress. In this study, we examined the effect of quercetin, a polyphenplic antioxidant anti fibrosis compund in fruits and vegetables, on the 5/6 nephrectomy-induced CKD progression model rats through modulation of Nrf2 expression.

Methods: Male Sprague-Dawley rats were randomly divided into normal control group (C), untreated 5/6 nephrectomy (Nx), quercetin-treated 5/6 nephrectomy (100 mg/kgBW/day orally) (NxQ), and captopril-treated 5/6 nephrectomy (10 mg/kgBW/day orally) (NxK) for 8 weeks. At the end of study, all animals were sacrified. Urine, blood, and kidney tissues were taken for examination of proteinuria, plasma creatinine, urea, malondialdehyde (MDA), glutathione peroxidase (GPx) activity, Nrf2, Keap1, heme oxygenase-1 (HO-1) expressions, and renal fibrosis.

Results: Quercetin administration did not affect the level of protein in urine, plasma creatinine, and urea. However, it tended to reduce the level of MDA, increase GPx activity, Nrf2, Keap1, and HO-1 expression as well as the degree of fibrosis.

Conclusion: In 5/6 nephrectomized rats, quercetin tended to ameliorate the level of MDA, GPx activity, Nrf2, Keap1, and HO-1 expression. In addition, quercetin tended to decrease the degree of fibrosis in the remnant kidney.


Keywords


chronic kidney disease; nephrectomy; Nrf2; oxidative stress; quercetin

Full Text:

PDF

References


  1. Quiroz Y, Ferrebuz A, Vaziri ND, Iturbe BR. Effect of chronic antioxidant therapy with superoxide dismutase-mimetic drug, tempol, on progression of renal disease in rats with renal mass reduction. Nephron Exp Nephrol. 2009;112:e31–e42. https://doi.org/10.1159/000210577
  2. K/DOQI. Clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. National Kidney Foundation; 2008. New York.
  3. Rivera JR, Ortiz A, Egido J. Antioxidant in kidney disease: the impact of bardoxolone methyl. Int J Nephrol. 2012.
  4. Kementerian Kesehatan RI. Badan Penelitian dan Pengembangan. Riskesdas 2013. Jakarta. Indonesian.
  5. Aminzadeh MA, Nicholas SB, Norris KC, Vaziri ND. Role of impaired Nrf2 activation in the pathogenesis of oxidative stress and inflammation in chronic tubule-interstitial nephropathy. Nephrol Dial Transpl. 2013. https://doi.org/10.1093/ndt/gft022
  6. Glorieux G, Mullen W, Duranton F, Filip S, Gayrard N, Husi H, Schepers E, et al. New insights in molecular mechanisms involved in chronic kidney disease using high-resolution plasma proteome analysis. Nephrol Dial Transplant. 2015;30:1842–52. https://doi.org/10.1093/ndt/gfv174.14
  7. Soetikno V, Sari FR, Lakshmanan AP, Arumugam S, Harima M, Suzuki K, et al. Curcumin alleviate oxidative stress, inflammation, and renal fibrosis in remnant kidney through the Nrf2-keap1 pathway. Mol Nutr Food Res. 2013;57:1649–59. https://doi.org/10.1002/mnfr.201200540
  8. Ma Q. Role of Nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol. 2013;53:401–26. https://doi.org/10.1146/annurev-pharmtox-011112-140320
  9. Boots AW, Haenen GRMM, Bast A. Health effect of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol. 2008;585:325–37. https://doi.org/10.1016/j.ejphar.2008.03.008
  10. Sriraksa N, Wattanathorn J, Muchimapura S, Tiamkao S, Brown K, Chaisiwamongkol K. Cognitive enhancing effect of quercetin in a rat model of parkinson's disease induced by 6-hydroxydopamine. Evidence-Based Complementary and Alternative Medicine. 2012.
  11. Lin SY, Wang YY, Chen YC, Chuang YH, Pan PH, Chen CJ. Beneficial effect of quercetin on cholestatic liver injury. Journal of Nutritional Biochemistry. 2014.
  12. Chen SF, Nien S, Wu CH, Liu CL, Chang YC, Lin YS. Reappraisal of the anticancer efficacy of quercetin in oral cancer cells. Journal of the Chinese Medical Association. 2013;76:146–52. https://doi.org/10.1016/j.jcma.2012.11.008
  13. Kleemann R, Verschuren L, Morrison M, Zadelaar S, Erk MJV, Wielinga PY, Kooistra T. Anti-inflammatory, anti-proliverative and anti-atherosclerotic effect of quercetin in human in vitro and in vivo models. Atherosclerosis. 2011;218:44–52. https://doi.org/10.1016/j.atherosclerosis.2011.04.023
  14. Gargouri B, Mansour RB, Abdallah FB, Elfekih A, Lassoued S, Khaled H. Protective effect of quercetin against oxidative stress caused by dimethoate in human peripheral blood lymphocytes. Lipids in Health and Disease. 2011. https://doi.org/10.1186/1476-511X-10-149
  15. Tanigawa S, Fujii M, Hou DX. Action of Nrf2 and keap 1 in ARE-medaited NQO1 expression by quercetin. Free Radical Biology & Medicine. 2007;42:1690–1703. https://doi.org/10.1016/j.freeradbiomed.2007.02.017
  16. Wang C, Pan Y, Zhang QY, Wang FM, Kong LD. Quercetin and allopurinol ameliorate kidney injury in STZ-treated rats with regulation of renal NLRP3 inflammasome activation and lipid accumulation. PLoS One. 2012;7(6):e38285. https://doi.org/10.1371/journal.pone.0038285
  17. Gibson-Corley KN, Olivier AK, Meyerholz DK. Principles for valid histopathologic scoring in research. Vet Pathol. 2013 Nov;50(6):1007-15 https://doi.org/10.1177/0300985813485099
  18. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and 2-ΔΔCT method. Methods. 2001;25:402–8. https://doi.org/10.1006/meth.2001.1262
  19. Fedorova LV, Tamirisa A, Kennedy DJ, Haller ST, Budnyy G, Shapiro JI, et al. Mitochondrial impairment in the five-sixth nephrectomy model of chronic renal failure: proteomic approach. BMC Nephrology. 2013;14:209. https://doi.org/10.1186/1471-2369-14-209
  20. Rangan GK, Wang Y, Harris DCH. Dietary quercetin augment activator protein-1 and doesn't reduce NF-κB in the renal cortex of rats with established chronic glomerular disease. Nephron. 2002;90:313–9. https://doi.org/10.1159/000049067
  21. Amann K, Gassmann P, Buzello M, Orth SR, Tornig J, Gross ML, et al. Effect of ACE inhibition and bradykinin antagonism on cardiovascular changes in uremic rats. Kidney International. 2000;58:153–61. https://doi.org/10.1046/j.1523-1755.2000.00163.x
  22. Kim HJ, Vaziri ND. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol. 2010;298:F662–71. https://doi.org/10.1152/ajprenal.00421.2009
  23. Ahmed AK, Kamath NS, El Kossi M, El Nahas AM. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant. 2010 Dec;25(12):3977-82. https://doi.org/10.1093/ndt/gfp511
  24. Palmer BF. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers: what to do if serum creatinine and or serum potassium concentration rises. Nephrol Dial Transplant. 2003;18:1973–5. https://doi.org/10.1093/ndt/gfg282
  25. Meyer TW, Hostetter TH. Uremia. N Engl J Med. 2007;357:1316–25. https://doi.org/10.1056/NEJMra071313
  26. Sindhu RK, Ehdaie A, Farman F, Dhaliwal KK, Nguyen T, Zhan CD, et al. Expression of catalase and glutathione peroxidase in renal insufficiency. Biochimica et Biophysica Acta. 2005:86–92. https://doi.org/10.1016/j.bbamcr.2004.08.013
  27. Cho MH. Renal fibrosis. Korean J Pediatr. 2010;53(7):735–40. https://doi.org/10.3345/kjp.2010.53.7.735





Copyright (c) 2017 Vivian Soetikno

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All articles and issues in Medical Journal of Indonesia have unique DOI number registered in Crossref.
 
Romeo
 
http://mji.ui.ac.id/journal/index.php/mji/pages/view/stat
Unique Visitors